antibodies (nanobodies) that target the transferrin receptor, which is responsible for the transport of iron into the brain, as another type of vector to deliver drugs to the CNS. Both LDL and ...

PCSK9 reduces the number of low-density lipoprotein (LDL) receptors, increasing circulating ... Treatment with the PCSK9-blocking antibody, evolocumab — which is approved to treat ...

Familial hypercholesterolemia results from gene mutations approximately halving the number of functional LDL receptors in heterozygotes and a greater lack in homozygotes. Reduced receptor-mediated ...

The resulting oxidatively modified (ox) LDL is recognized by specialized receptors on the surface of macrophage cells. Receptor recognition promotes unregulated uptake (endocytosis) of the oxLDL by ...